Prefrontal cortex infusion of beta-hydroxybutyrate, an endogenous NLRP3 inflammasome inhibitor, produces antidepressant-like effects in a rodent model of depression

Naofumi Kajitani1  |  Masaaki Iwata1  |  Akihiko Miura1  |  Kyohei Tsunetomi1  |  Takehiko Yamanashi1  |  Ryoichi Matsuo1  |  Tsuyoshi Nishiguchi1  |  Saki Fukuda1  |  Mayu Nagata1  |  Midori Shibushita1  |  Takahira Yamauchi2  |  Shenghong Pu1  |  Yukihiko Shirayama3  |  Ken Watanabe4  |  Koichi Kaneko1

1Department of Neuropsychiatry, Faculty of Medicine, Tottori University, Yonago, Japan
2Department of Psychiatry, Nara Medical University School of Medicine, Kashihara, Japan
3Department of Psychiatry, Teikyo University Chiba Medical Center, Ichihara, Japan
4Watanabe Hospital, Tottori, Japan

Correspondence
Masaaki Iwata, Department of Neuropsychiatry, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan.
Email: yanmasa@f8.dion.ne.jp

Funding information
GlaxoSmithKline foundation; SENSHIN Medical Research Foundation; Japan Society for the Promotion of Science, Grant/Award Number: JP15K19729 and JP17K10273

Abstract

Aims: Neuroinflammation is deeply related to the pathophysiology of depression. Beta-hydroxybutyrate (BHB), which is an endogenous ketone body, exerts anti-inflammatory effects, and peripheral administration of BHB induces antidepressant effects in an animal model of depression; however, it is unclear whether BHB specifically mediates these actions in the brain. Thus, we administered BHB directly into the brain in a rodent model of depression using a chronic unpredictable stress (CUS) paradigm.

Methods: BHB was continuously microinjected into the prefrontal cortex (PFC) using osmotic pumps for 21 days. Behavioral testing included the forced swim test (FST) and the open field test (OFT); the levels of pro-inflammatory cytokines, such as interleukin 1β (IL-1β) and tumor necrosis factor α (TNF-α), were quantified in the PFC, and the concentration of corticosterone in blood serum was measured.

Results: BHB administration into the PFC significantly decreased immobility time in the FST, without significantly altering locomotor activity assessed in the OFT. Also, CUS significantly increased the levels of TNF-α in the PFC and decreased serum corticosterone levels; these changes were attenuated by BHB administration. These findings suggest that a small amount of BHB administered into the PFC directly produces antidepressant effects, possibly through anti-inflammatory mechanisms, and can improve hypothalamus-pituitary-adrenal axis responses.

Conclusion: BHB may be a novel therapeutic candidate for the treatment of depression based on the neuro-inflammatory hypothesis, and the PFC is a region implicated in the antidepressant action of BHB.

KEYWORDS
beta-hydroxybutyrate, depression, inflammasome, NLRP3, prefrontal cortex, stress
1 | INTRODUCTION

Depression is a mental illness involving symptoms of depressed mood and diminished interest or pleasure. Although the pathophysiology of depression is still unclear, stressful life events can be risk factors that induce neuroplastic changes in the brain, such as decreased neurogenesis in the hippocampus and a loss of dendritic spine density. Current antidepressant treatment based on the monoamine hypothesis produces inadequate improvement in 1/3 of depressive patients; thus, the identification of alternative mechanisms of depression is required to develop novel therapeutic strategies. It is well known that depression often coexists with chronic diseases such as diabetes, cancer, heart disease, and rheumatoid arthritis, and these diseases share a feature of chronic inflammation, suggesting that immune reactivity and inflammatory processes may be common factors underlying the neurophysiological changes associated with depression. Recent studies have shown a relationship between brain inflammation and depression, as administration of interleukin-1β (IL-1β), a pro-inflammatory cytokine, in the brain can cause depressive-like behavior. In humans, increases in inflammatory cytokine expression, including IL-1β and IL-18, in the peripheral blood of depressed patients have been reported; these expression levels become normalized with recovery from depression. It has also been shown that nucleotide-binding domain, leucine-rich repeat and pyrin domain containing 3 (NLRP3), a pattern recognition receptor involved in the production of IL-1β and IL-18, are increased in serum; again, these changes can be normalized by treatment with tricyclic antidepressants. NLRP3 reacts to various danger signals to form a protein complex called an inflammasome, which generates inflammatory cytokines through the activation of caspase-1. Our previous study demonstrated that stress increases adenosine tri-phosphate (ATP) production, which acts as a danger signal in the prefrontal cortex (PFC) and hippocampus. Furthermore, the activation of NLRP3 and the increase of IL-1β and tumor necrosis factor α (TNF-α) in the hippocampus are induced by stress, while inhibition of NLRP3 inflammasome activity by ATP receptor antagonists, purinergic Type 2X7 receptor (P2X7R) antagonists, or the neutralization of IL-1β by an IL-1β antibody improves depressive-like behaviors. Thus, inhibiting ATP-P2X7R-NLRP3 signaling is a possible strategy for treating depression induced by stress.

Beta-hydroxybutyrate (BHB) is an endogenous ketone body that supports mammalian cell metabolism during states of energy deficiency, such as those induced by fasting or exercise. In recent years, several reports have shown that BHB may have an antidepressant effect, likely by inhibiting the activation of the NLRP3 inflammasome. In addition, our previous study showed that peripheral administration of BHB decreased inflammatory cytokine concentrations in the hippocampus, such as IL-1β and TNF-α, and improved depressive and anxiety-like behaviors in a rodent model of chronic unpredictable stress (CUS). While BHB is thought to have potential antidepressant actions, it is not known whether peripherally administered BHB can act directly in the brain or if its effects are mediated strictly through peripheral mechanisms. Therefore, in this study, we aimed to investigate whether direct, local infusion of BHB into the brain is effective in alleviating stress-induced depressive-like behaviors.

Although the specific brain regions associated with depression have not been identified, human studies have shown certain morphological changes, such as hippocampal atrophy and blood flow reduction in the frontal lobe. In animal stress models, an increase in inflammatory cytokine concentration in the PFC and hippocampus has been observed, and activation of the NLRP3 inflammasome occurs in the PFC. Recently, it has been reported that PDF administration of ketamine produces rapid and potent antidepressant effects. Because inflammation in the PFC may be related to the pathophysiology of depression, and administration of ketamine in the PFC induces an antidepressant effect, we aimed to confirm whether the antidepressant action of BHB can be mediated through direct administration into the PFC in CUS model rats.

2 | MATERIALS AND METHODS

The experimental procedures were conducted in accordance with the Institutional Animal Care Guidelines and were approved by the Tottori University Animal Care and Use Committee (Approval number h31-Y012). Efforts were made to minimize animal suffering.

2.1 | Animals

Male Sprague-Dawley rats, 7-8 weeks of age, were obtained from Charles River Laboratories. Two rats were housed per cage on a
12 h/12 h light/dark cycle (lights on at 7:30 AM). Temperature was maintained at 25°C, and food and water were freely available. One week before the experimental procedures, rats were acclimatized to the laboratory. Their mean body weight was about 350 g before the start of experiments.

2.2 Reagents

DL-BHB (Tokyo Chemical Industry) was dissolved in phosphate-buffered saline (PBS) (NaCl 137 mM, KCl 2.7 mM, Na$_2$HPO$_4$.12H$_2$O 8.1 mM, KH$_2$PO$_4$.1.47 mM). BHB was prepared at a concentration of 80 mg/mL based on a previous report. Both BHB and PBS solutions were adjusted to pH 7.3.

2.3 Cannulation surgery

Animals were anesthetized with an intramuscular (im) injection of ketamine/xylazine (80/6 mg/kg) and held in a stereotactic frame. Cannulas were inserted into the PFC (coordinates: anteroposterior + 3.2 mm, dorsolateral ± 0.6 mm from bregma, ventral 4.0 mm from the skull surface) (Figure 1). The cannulas were homemade, with a length of 4 mm. Each arm of the cannula was connected to an osmotic pump (ALZET® Osmotic Pumps Model 2006. Nominal pumping rate: 0.15 μL/h; duration: six weeks). One pump was used for each cannula (two pumps in total per rat). The pumps were filled with PBS or BHB solutions. Antibacterial penicillin G (6000 units) (Meiji Seika Pharma Co., Ltd.) was injected before surgery, and an analgesic (carprofen, 5 mg/kg; Zoetis Japan Co., Ltd.) was administered for three days after surgery. Rats were allowed a recovery period of one week after surgery before starting the CUS paradigm.

2.4 Experimental groups

Rats were divided into four groups: (a) nonstress + PBS, (b) nonstress + BHB, (c) CUS + PBS, (d) CUS + BHB. Behavioral tests were conducted two to three weeks after the start of the CUS paradigm. Blood samples were collected after all behavioral tests were completed (Figure 2A).

2.5 Chronic unpredictable stress (CUS)

The CUS paradigm is a rodent model of depression in which rats are exposed to a variable sequence of two mild and unpredictable stressors per day, preventing habituation, as previously described. The stressors included cage tilt (tilting the cage 45°, overnight), crowding (ten animals per cage), cold temperature exposure (one hour at 4°C), immobilization in tapered plastic film tubes (one hour), exposure to wet bedding (wetting the floor overnight or during the daytime), food deprivation (overnight), water deprivation (overnight), isolation (overnight), cage rotation (one hour), and lights off during the daytime or lights on overnight. These stressors were adapted from our previous study. Control rats were handled daily.

2.6 Behavioral tests

2.6.1 Forced swim test (FST)

Rats were placed for five minutes in a plastic bucket filled with water (24°C, 34 cm depth). Immobility was defined as the point at which the rat ceased struggling and stayed in the water without movement, except those necessary to keep their heads above water. Tests were recorded and scored by a blinded observer. The water was changed after each trial.

2.6.2 Open field test (OFT)

Rats were placed in an open field apparatus (90 cm × 90 cm × 45 cm) and allowed to explore for ten minutes. The test was conducted in a bright environment. Locomotor activity (total distance travelled) was assessed using TopScan Suite (CleverSys, Inc). The open field apparatus was cleaned after each trial.

2.7 Western blotting

Western blotting was conducted as previously described. Briefly, the frozen PFC tissue samples were homogenized in ice-cold buffer. The protein samples were separated using 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), then transferred to nitrocellulose membranes. The membranes were incubated with primary antibodies for IL-1β (ab9722; 1:2,500 dilution, ie, 0.2 μg/mL, Abcam) and TNF-α (AB1837P; 1:2,500, ie 0.2 μg/mL, Merck Millipore), followed by incubation with an anti-rabbit secondary antibody (ab16284; 1:10,000 dilution, ie 0.1 μg/mL, Abcam). Densitometric analysis of Western blot bands was performed using ImageJ software, version 1.51 (National Institutes of Health).

2.8 Serum corticosterone measurement

After the behavioral tests were completed, blood was collected (5:00 PM-6:00 PM) from the site of decapitation and stored overnight at 4°C. The next day, samples were centrifuged at 500 g for 1 min at 4°C to remove debris, the supernatant was collected, and serum corticosterone levels were measured by a chemiluminescent enzyme immunoassay (CLEIA) method based on the manufacturer’s instructions (Roche Diagnostics K.K).
2.9 | Statistical analyses

All statistical analyses were conducted using Statistical Package for the Social Sciences (SPSS) Statistics 19.0. For comparisons among the four groups, analyses of variance were conducted, followed by Tukey’s post hoc tests. The data are presented as means ± standard error of the mean (SEM). P-values < .05 were considered statistically significant.

3 | RESULTS

3.1 | Rats exposed to CUS displayed weight loss

We examined the influence of the CUS paradigm on rats’ body weight (BW). At the beginning of the experiment, there were no significant differences in BW among the four groups (F(3,31) = 0.162, P = .921, n = 8). Compared with the nonstress group, the CUS group lost weight during the first week after starting the CUS paradigm. After that initial loss, the nonstress and CUS groups gained weight in parallel, but continued to show significant differences in BW (Figure 2B). This result is similar to those observed in our previous study.

3.2 | BHB microinjection into the PFC induced antidepressant effects in the FST

Previously, we demonstrated an antidepressant effect in the FST following peripheral administration of BHB; however, it was unclear whether this resulted from a direct effect in the central nervous system (CNS). In order to assess whether the effects were direct, we conducted the FST following cannulation and microinjection of BHB into the PFC. Compared to the nonstress + PBS group, the CUS + PBS group showed no difference in immobility time (P = .857). However, in both the nonstress and the CUS groups,

FIGURE 2 | Experimental design and body weight tracking. (A) Schematic of the experimental design. Rats were divided into four groups: (1) nonstress + PBS, (2) nonstress + BHB, (3) CUS + PBS, (4) CUS + BHB. Behavioral tests were conducted two to three weeks after the beginning of the stress paradigm; brain and blood samples were collected after all behavioral tests were completed. (B) Body weight tracking. Compared to the nonstress group, the CUS group started to lose weight one week later and then gained weight. However, the nonstress group and the CUS group continued to exhibit differences in body weight. P < .001 for comparisons between nonstress + PBS vs CUS + PBS, nonstress + PBS vs CUS + BHB, nonstress + BHB vs CUS + PBS, and nonstress + BHB vs CUS + BHB. Error bars represent the standard error of the mean (SEM). PBS: phosphate-buffered saline; BHB: beta-hydroxybutyrate; CUS: chronic unpredictable stress

FIGURE 3 | Forced swim test and assessment of locomotor activity. (A) Forced swim test. Although CUS did not induce stress responses compared with nonstress controls, BHB administration shortened the immobility time in both the nonstress and the CUS group. P < .05 for comparisons between nonstress + PBS vs CUS + PBS, nonstress + BHB and CUS + PBS vs CUS + BHB. (B) Open field test. The OFT was conducted to determine whether locomotor activity correlated with the changes in immobility time observed in the FST. There was no significant difference between the groups. Error bars represent the standard error of the mean (SEM). FST, forced swim test; CUS: chronic unpredictable stress; BHB: beta-hydroxybutyrate; PBS: phosphate-buffered saline; OFT, open field test
BHB administration into the PFC resulted in significantly shorter immobility times (F(3,24) = 6.484, P < .05, n = 6-7) (Figure 3A). The results demonstrate that BHB exerts antidepressant effects by directly acting in the CNS when administered in the PFC, confirming our hypothesis.

3.3 | No difference in locomotor activity was observed

The OFT was performed to determine whether changes in locomotor activity correlated with changes in immobility time observed in the FST. Locomotor activity was increased in the CUS group compared with the nonstress group. In addition, locomotor activity was increased following BHB administration; however, there was no significant difference between the treated CUS and no-stress groups. Although there was a small but nonsignificant difference in the OFT, the results were not consistent with the differences in immobility times observed in the FST (F(3,29) = 1.516, P = .234, n = 7-8) (Figure 3B).

3.4 | PFC BHB administration attenuated the increase in TNF-α induced by CUS

To determine whether stress affects inflammatory cytokine levels in the brain and whether intracerebral administration of BHB has any effect on these cytokine levels, Western blots of PFC samples were performed. The levels of TNF-α in the PFC were significantly increased in rats exposed to CUS compared with nonstressed control rats (P < .05). In addition, BHB administration into the PFC significantly attenuated the upregulation in TNF-α levels induced by CUS (P < .05) (Figure 4B). On the other hand, we found no significant change in IL-1β levels in the PFC (F(3,30) = 1.277, P = .302, n = 7-8) (Figure 4A).

3.5 | CUS changed the hypothalamus-pituitary-adrenal (HPA) axis response, which was attenuated by BHB administration

Stress responses can also be evaluated by quantifying HPA axis activity inferred by the levels of corticosterone in the blood. In this study, serum corticosterone levels were significantly reduced following CUS exposure compared with nonstressed control rats; this change was completely attenuated by BHB administration in the PFC (F(3,31) = 4.655 P < .05 n = 8) (Figure 5). In general, stress initiates adaptive processes, such as corticosterone secretion, that allow the organism to physiologically respond to threats; however, long-term and cumulative stress is known to reduce or dysregulate HPA axis activity to limit the deleterious effects of prolonged corticosterone secretion. In this study, the decreased levels of corticosterone in serum caused by CUS were attenuated by the administration of BHB, possibly through reduction of stress responses.
Inflammation is now known to be involved in the pathophysiology of depression, and BHB administration can induce antidepressant effects by suppressing NLRP3, a critical complex that senses stress molecules and mediates inflammatory responses. Although BHB reportedly exerts antidepressant effects following peripheral administration, it was not previously clear whether it directly acted in the brain. In this study, we administered BHB directly into the PFC to exclude the possibility of peripheral action. We showed that depressive behavior in the FST was improved by the direct administration of BHB into the PFC. In addition, the levels of TNF-α, a pro-inflammatory cytokine that is upregulated in the PFC by CUS, were reduced by direct administration of BHB. Also, impaired responsiveness of the HPA axis induced by CUS was attenuated by BHB administration. These results indicate that the antidepressant effects of BHB can be mediated directly in the brain, likely through anti-inflammatory mechanisms, and that the PFC is at least partially responsible for mediating BHB’s effects in the CNS.

Inflammatory cytokines, such as IL-1β, are implicated in the pathophysiology of depression. NLRP3, a complex of pattern recognition receptors, and its active form, the inflammasome play critical roles in activating IL-1β and IL-18, and have been implicated in multiple chronic inflammatory diseases, such as infectious diseases, autoimmune diseases, diabetes, Alzheimer’s disease, and arteriosclerosis, all of which are common comorbidities of depression. Thus, NLRP3 may be a key component that mediates inflammation in depression. NLRP3 is expressed mainly in microglia and astrocytes in the brain; it detects various dangerous substances and initiates inflammatory responses. When NLRP3 forms an inflammasome, procaspase-1 is converted to mature caspase-1, which, in turn, leads to the maturation of pro-IL-1β to IL-1β. The presence of IL-1β in the brain is associated with depressive behavior, and inhibition of the NLRP3 inflammasome or suppression of inflammatory cytokine expression reduces depressive-like behaviors.

BHB is a ketone body synthesized in the liver of mammals that is used as an alternative energy source in the brain in states of glucose deprivation. BHB has anti-inflammatory and neuroprotective effects and may have therapeutic potential in the treatment of degenerative diseases such as Huntington’s disease, Parkinson’s disease, and Alzheimer’s disease; thus, BHB is thought to affect the CNS. There is evidence that a ketogenic diet, which leads to elevated levels of BHB in the serum and brain, produces antidepressant effects, as seven days on a ketogenic diet increases the levels of serum BHB and decreases immobility time in the FST. In addition, adult offspring previously exposed to a prenatal ketogenic diet exhibits reductions in anxiety-like behaviors in the OFT and depressive-like behaviors in the FST. In that study, many neuroanatomical differences were shown to exist between control animals and the offspring of those exposed to a ketogenic diet, including volumetric enlargement of the cerebellum, and reductions in the hypothalamus and corpus callosum. Recent reports have shown that BHB itself also induces antidepressant effects in animals. In our previous study, we confirmed that chronic peripheral administration of BHB decreased depressive-like behavior caused by CUS, and that BHB administration suppressed the increase in inflammatory cytokine expression induced by acute stress in this model. Another group showed that three weeks of repeated intraperitoneal BHB administration ameliorated depressive behaviors in a mouse model of depression involving spatial restraint stress and dexamethasone administration, as BHB administration increased histone3-lysine9-β-hydroxybutyrylation, leading to upregulated expression of brain-derived neurotrophic factor (BDNF).

BHB is transported into the brain via a monocarboxylate transporter expressed at the blood-brain barrier, and it has already been confirmed that peripheral administration leads to an increased BHB concentration in the brain. However, the rate at which BHB is transported to the brain and the kinetics of its distribution to various regions are not clear. In addition, because inflammatory cytokines are present in the periphery and can affect the brain through several mechanisms, BHB administered peripherally may act by reducing inflammatory cytokines outside the CNS. Recently, it has been shown that peripheral inflammatory mediators can be transmitted to the brain via the afferent vagus nerve, and the brain modulates peripheral inflammation via the efferent vagus nerve. Evidence that peripheral inflammation can affect the brain is increasing, and it is important to clarify whether substances that modulate anti-inflammatory effects can act directly in the brain to reduce depressive-like symptoms. If the anti-inflammatory effect of BHB is mediated in the brain to cause an antidepressant response, it was hypothesized that intracerebral administration would result in antidepressant effects, which we confirmed in this study.

Here, BHB was administered into the prelimbic region of the PFC. Morphological changes in the PFC of depressed patients include decreased volume and decreased blood flow. Postmortem analysis of the PFC of suicide victims has shown elevated levels of inflammatory cytokines such as IL-1β, IL-6, and TNF-α, and suicide victims that have suffered from depression and schizophrenia exhibit increased microglial reactivity. Increased microglial activation and inflammatory cytokine expression in the PFC have been linked to psychiatric disorders. In animal experiments, dendritic atrophy occurs in the PFC in response to stress. There are also reports of increased NLRP3 inflammasome activity and elevated inflammatory cytokine levels, such as IL-1β, in the PFC after exposure to stress. Antidepressant effects are also observed following administration of ketamine in the PFC, and reports that have confirmed the reduction of stress-induced inflammatory cytokines and depressive-like behavior due to the lack of toll-like receptor (TLR) in the PFC suggest that the PFC may be an important target for antidepressant action.

The CUS paradigm employed in this study is often used as a depression model with high face validity, construct validity, and predictive validity; however, we could not confirm the depression-inducing effect of the CUS paradigm, especially in the behavioral testing, possibly because intracerebral injection is highly invasive and the surgery itself may have induced stress responses.
Also, because the reliable operation period of the osmotic pumps we used was only six weeks, we shortened the CUS paradigm to three weeks, which may partially explain the ineffectiveness of the CUS model. Despite such limitations, BHB showed a strong antidepressant effect in the FST in this study. The OFT was also performed to rule out the effects of increased locomotor activity, and there were no significant differences between groups.

In addition to the behavioral tests, changes in pro-inflammatory cytokines and corticosterone levels were examined in vivo. In this study, CUS did not affect IL-1β levels, but induced a significant increase in TNF-α levels. On the other hand, BHB attenuated the upregulation of TNF-α. The fact that we observed changes in TNF-α and no effects on IL-1β levels are consistent with the results reported in our previous studies. While IL-1β levels typically increase in response to stress, the change is transient, as compensatory mechanisms quickly restore the concentration to basal levels. On the other hand, since TNF-α levels continue to change long after the initial insult, the differences are relatively easier to observe. In this study, while IL-1β levels tended to increase slightly in response to stress and decreased following BHB administration, no significant differences were observed. Previous studies have reported that P2X7R inhibitors, which can regulate the ATP-NLRP3 pathway, suppress TNF-α upregulation. Changes in TNF-α levels are thought to be downstream of IL-1β and may be controlled by inhibition of the ATP-NLRP3 pathway. Thus, it is assumed that stress increases TNF-α and, possibly to a lesser extent, IL-1β levels in the PFC and can cause neuropathy, but BHB suppresses neuroinflammation and exerts a neuroprotective effect.

The PFC is rich in glucocorticoid receptors and it is thought that the PFC is involved in the regulation of the HPA axis, along with the hippocampus. Chronic stress has been shown to reduce the expression levels of glucocorticoid receptors in both the PFC and the hippocampus, and deficiency of glucocorticoid receptors in the PFC is reported to prolong immobility time in the FST. In some chronic stress models in animals, it has also been reported that HPA activity stops increasing over time. In our study, the CUS group exhibited significantly lower corticosterone levels compared with the nonstress group, while BHB administration attenuated this decrease in corticosterone production, even under the stress condition. This suggests that BHB may suppress the alterations in corticosterone receptor expression in the PFC caused by stress and may help maintain HPA system function.

There are several methodological limitations to this study. We cannot fully claim that improvements in abnormal cytokine levels and HPA dysfunction are responsible for the antidepressant effects of BHB because it is not clear whether these changes are the main contributors to the antidepressant effect or just a consequence of other mechanisms of change; further study is required to determine causal relationships. Also, a recent study reported that immobility in the FST may not only be related to “despair,” but may also be interpreted as an “adaptive learned response”. This is a very important distinction, and we need to cautiously interpret the results of the FST.
number h31-Y012). Efforts were made to minimize animal suffering.

ORCID
Masaaki Iwata https://orcid.org/0000-0002-6143-0181

REFERENCES
1. Hammen C. Stress and depression. Annu Rev Clin Psychol. 2005;1:293–319.
2. Kessler RC. The effects of stressful life events on depression. Annu Rev Psychol. 1997;48:191–214.
3. Duman RS. Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression. Dialogues Clin Neurosci. 2009;11(3):239–55.
4. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–17.
5. Iwata M, Ota KT, Duman RS. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav Immun. 2013;31:105–14.
6. Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KR, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry. 2005;58(3):175–89.
7. Koo JW, Duman RS. IL-1beta is an essential mediator of the antineuropenic and anhedonic effects of stress. Proc Natl Acad Sci USA. 2008;105(2):751–6.
8. Al-Hakeim HK, Twajej AJ, Al- AH. Reduction in serum IL-1β, IL-6, and IL-18 levels and Beck Depression Inventory-II score by combined sertraline and ketoprofen administration in major depressive disorder: A clinical trial. Neurol Psychiatry Brain Res. 2018;30:148–53.
9. Alcocer-Gómez E, Casas-Barquero N, Williams MR, Romero-Guillena SL, Cañadas-Lozano D, Bullón P, et al. Antidepressants induce autophagy dependent-NLRP3-inflammasome inhibition in Major depressive disorder. Pharmacol Res. 2017;121:114–21.
10. Alcocer-Gómez E, de Miguel M, Casas-Barquero N, Núñez-Vasco J, Sánchez-Alcazar JA, Fernández-Rodríguez A, et al. NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder. Brain Behav Immun. 2014;36:111–7.
11. Iwata M, Ota KT, Li Y, Yukawa F, Li N, Dutheil S, et al. Psychological stress activates the inflammasome via release of adenosine triphosphate and stimulation of the purinergic type 2X7 receptor. Biol Psychiatry. 2016;80(1):12–22.
12. Newman JC, Verdin E. Ketone bodies as signaling metabolites. Trends Endocrinol Metab. 2014;25(1):42–52.
13. Cotter DG, Schugger RC, Crawford A. Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2013;304(8):H1060–H1076.
14. Chen L, Miao Z, Xu X. Beta-hydroxybutyrate alleviates depressive behaviors in mice possibly by increasing the histone3-lysine9-beta-hydroxybutyrylation. Biochem Biophys Res Commun. 2017;490(2):117–22.
15. Yamanashi T, Iwata M, Kamiya N, Tsunetomi K, Kajitani N, Wada N, et al. Beta-hydroxybutyrate, an endogenic NLRP3 inflammasome inhibitor, attenuates stress-induced behavioral and inflammatory responses. Sci Rep. 2017;7(1):7677.
16. Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodiogai M, Kim D, et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015;21(3):263–9.
17. Schweitzer I, Tuckwell V, O’Brien J, Ames D. Is late onset depression a prodrome to dementia? Int J Geriatr Psychiatry. 2002;17(11):997–1005.
18. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160(8):1516–8.
19. Mayberg HS, Lewis PJ, Regenold W, Wagner HN. Paralimbic hyperfusion in unipolar depression. J Nucl Med. 1994;35(6):929–34.
20. Pan Y, Chen XY, Zhang QY, Kong LD. Microglial NLRP3 inflammasome activation mediates IL-1 beta-related inflammation in prefrontal cortex of depressive rats. Brain Behav Immun. 2014;41:90–100.
21. Li R, Wang X, Qin T, Qu R, Ma S. Apigenin ameliorates chronic mild stress-induced depressive behavior by inhibiting interleukin-1beta production and NLRP3 inflammasome activation in the rat brain. Behav Brain Res. 2016;296:318–25.
22. Sahin C, Albayrak O, Akdeniz TF, Akbulut Z, Yanikkaya Demirel G, Aricioglu F. Agmatine reverses sub-chronic stress induced nod-like receptor protein 3 (NLRP3) activation and cytokine response in rats. Basic Clin Pharmacol Toxicol. 2016;119(4):367–75.
23. Fukushima K, Iijima M, Chaki S. The antidepressant effects of an mGlu2/3 receptor antagonist and ketamine require AMPA receptor stimulation in the mPFC and subsequent activation of the 5-HT neurons in the DRN. Neuropsychopharmacology. 2016;41(4):1046–56.
24. Park S, Kim DS, Daily JW. Central infusion of ketone bodies modulates body weight and hepatic insulin sensitivity by modifying hypothalamic leptin and insulin signaling pathways in type 2 diabetic rats. Brain Res. 2011;1401:95–103.
25. Davis BK, Wen H, Ting J. The inflammasome NLIRS in immunity, inflammation, and associated diseases. Annu Rev Immunol. 2011;29:707–35.
26. Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell. 2014;157(5):1013–22.
27. Wen H, Ting J, O’Neill LA. A role for the NLRP3 inflammasome in metabolic diseases—did Warburg miss inflammation? Nat Immunol. 2012;13(4):352–7.
28. Tan M-S, Yu J-T, Jiang T, Zhu X-C, Tan L. The NLRP3 inflammasome in Alzheimer’s disease. Mol Neurobiol. 2013;48(3):875–82.
29. Song L, Pei L, Yao S, Wu Y, Shang Y. NLRP3 Inflammasome in neurological diseases, from functions to therapies. Front Cell Neurosci. 2017;11:63.
30. Zhang Y, Liu L, Liu Y-Z, Shen X-L, Wu T-Y, Zhang T, et al. NLRP3 inflammasome mediates chronic mild stress-induced depression in mice via neuroinflammation. Int J Neuropsychopharmacol. 2015;18(8):pyv006.
31. Rojas-Morales P, Tapia E, Pedraza-Chaverri J. Beta-Hydroxybutyrate: A signaling metabolite in starvation response? Cell Signal. 2016;28(8):917–23.
32. Lim S, Chesser AS, Grima JC, Rappold PM, Blum D, Przedborski S, et al. D-beta-hydroxybutyrate is protective in mouse models of Huntington’s disease. PLoS ONE. 2011;6(9):e24620.
33. Tieu K, Perier C, Caspersen C, Teismann P, Wu DC, Yan SD, et al. D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest. 2003;112(6):892–901.
34. Zhang J, Cao Q, Li S, Lu X, Zhao Y, Juan G-S, et al. 3-Hydroxybutyryl methyl ester as a potential drug against Alzheimer’s disease via mitochondria protection mechanism. Biomaterials. 2013;34(30):7552–62.
35. Bostock EC, Kirkby KC, Taylor BV. The current status of the ketogenic diet in psychiatry. Front Psychiatry. 2017;8:43.
36. Murphy P, Likhodii S, Nylen K, Burnham WM. The antidepressant properties of the ketogenic diet. Biol Psychiatry. 2004;56(12):981–3.
37. White H, Venkatesh B, Jones M, Worrall S, Chuah T, Ordonez J. Effect of a hypertonic balanced ketone solution on plasma, CSF and brain beta-hydroxybutyrate levels and acid-base status. Intensive Care Med. 2013;39(4):727–33.
38. Banks WA, Kastin AJ, Broadwell RD. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation. 1995;2(4):241–8.

39. Rosas-Ballina M, Tracey KJ. Cholinergic control of inflammation. J Intern Med. 2009;265(6):663–79.

40. Pandey GN, Rizavi HS, Ren X, Fareed J, Hoppensteadt DA, Roberts RC, et al. Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. J Psychiatr Res. 2012;46(1):57–63.

41. Radley JJ, Rocher AB, Miller M, Janssen WGM, Liston C, Hof PR, et al. Repeated stress induces dendritic spine loss in the rat medial prefrontal cortex. Cereb Cortex. 2006;16(3):313–20.

42. Goldwater DS, Pavlides C, Hunter RG, Bloss EB, Hof PR, McEwen BS, et al. Structural and functional alterations to rat medial prefrontal cortex following chronic restraint stress and recovery. Neuroscience. 2009;164(2):798–808.

43. Moda-Sava RN, Murdock MH, Parekh PK, Fetcho RN, Huang BS, Huynh TN, et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science. 2019;364(6436):eaat8078.

44. Nie X, Kitaoka S, Tanaka K, Segi-Nishida E, Imoto Y, Ogawa A, et al. The innate immune receptors TLR2/4 mediate repeated social defeat stress-induced social avoidance through prefrontal microglial activation. Neuron. 2018;99(3):464–79.

45. Abella PA, Reus GZ, Quevedo J. Animal models as tools to study the pathophysiology of depression. Braz J Psychiatry. 2013;35(Suppl 2):S112–S120.

46. Hill MN, Hellemans KGC, Verma P, Gorzalka BB, Weinberg J. Neurobiology of chronic mild stress: parallels to major depression. Neurosci Biobehav Rev. 2012;36(9):2085–117.

47. Yin X, Guven N, Dietis N. Stress-based animal models of depression: Do we actually know what we are doing? Brain Res. 2016;1652:30–42.

48. Patel PD, Lopez JF, Lyons DM, Burke S, Wallace M, Schatzberg AF. Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain. J Psychiatr Res. 2000;34(6):383–92.

49. Ahima RS, Harlan RE. Charting of type II glucocorticoid receptor-like immunoreactivity in the rat central nervous system. Neuroscience. 1990;39(3):579–604.

50. Radley JJ, Sisti HM, Hao J, Rocher AB, McCall T, Hof PR, et al. Chronic behavioral stress induces apical dendritic reorganization in pyramidal neurons of the medial prefrontal cortex. Neuroscience. 2004;125(1):1–6.

51. Mizoguchi K, Ishige A, Aburada M, Tabira T. Chronic stress attenuates glucocorticoid negative feedback: involvement of the prefrontal cortex and hippocampus. Neuroscience. 2003;119(3):887–97.

52. Chiba S, Numakawa T, Ninomiya M, Richards MC, Wakabayashi C, Kunugi H. Chronic restraint stress causes anxiety- and depression-like behaviors, downregulates glucocorticoid receptor expression, and attenuates glutamate release induced by brain-derived neurotrophic factor in the prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39(1):112–9.

53. Boyle MP, Brewer JA, Funatsu M, Wozniak DF, Tsien JZ, Izumi Y, et al. Acquired deficit of forebrain glucocorticoid receptor produces depression-like changes in adrenal axis regulation and behavior. Proc Natl Acad Sci USA. 2005;102(2):473–8.

54. McKlveen JM, Myers B, Flak JN, Bundzikova J, Solomon MB, Seroogy KB, et al. Role of prefrontal cortex glucocorticoid receptors in stress and emotion. Biol Psychiatry. 2013;74(9):672–9.

55. Christoffel DJ, Golden SA, Russo SJ. Structural and synaptic plasticity in stress-related disorders. Rev Neurosci. 2011;22(5):535–49.

56. Anyan J, Amir S. Too depressed to swim or too afraid to stop? A re-interpretation of the forced swim test as a measure of anxiety-like behavior. Neuropsychopharmacology. 2018;43(5):931–3.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Kajitani N, Iwata M, Miura A, et al. Prefrontal cortex infusion of beta-hydroxybutyrate, an endogenous NLRP3 inflammasome inhibitor, produces antidepressant-like effects in a rodent model of depression. Neuropsychopharmacol Rep. 2020;40:157–165. https://doi.org/10.1002/npr2.12099